Questionable	O
diagnostic	O
benefit	O
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	B:C0004920
venom	I:C0004920
components	O
.	O

For	O
many	O
years	O
,	O
only	O
the	O
major	O
allergen	B:C0002092
rApi	O
m	I:C0002092
1	I:C0002092
has	O
been	O
available	O
on	O
the	O
ImmunoCAP	O
system	I:C0282574
for	O
routine	O
diagnosis	O
of	O
bee	O
venom	I:C1828283
(	I:C1828283
BV	I:C1828283
)	I:C1828283
allergy	I:C1828283
.	O

For	O
many	O
years	O
,	O
only	O
the	O
major	O
allergen	O
rApi	B:C0002092
m	I:C0002092
1	I:C0002092
has	O
been	O
available	O
on	O
the	O
ImmunoCAP	O
system	I:C0282574
for	O
routine	O
diagnosis	O
of	O
bee	O
venom	I:C1828283
(	I:C1828283
BV	I:C1828283
)	I:C1828283
allergy	I:C1828283
.	O

For	O
many	O
years	O
,	O
only	O
the	O
major	O
allergen	O
rApi	O
m	I:C0002092
1	I:C0002092
has	O
been	O
available	O
on	O
the	O
ImmunoCAP	B:C0282574
system	I:C0282574
for	O
routine	O
diagnosis	O
of	O
bee	O
venom	I:C1828283
(	I:C1828283
BV	I:C1828283
)	I:C1828283
allergy	I:C1828283
.	O

For	O
many	O
years	O
,	O
only	O
the	O
major	O
allergen	O
rApi	O
m	I:C0002092
1	I:C0002092
has	O
been	O
available	O
on	O
the	O
ImmunoCAP	O
system	I:C0282574
for	O
routine	O
diagnosis	B:C0011900
of	O
bee	O
venom	I:C1828283
(	I:C1828283
BV	I:C1828283
)	I:C1828283
allergy	I:C1828283
.	O

For	O
many	O
years	O
,	O
only	O
the	O
major	O
allergen	O
rApi	O
m	I:C0002092
1	I:C0002092
has	O
been	O
available	O
on	O
the	O
ImmunoCAP	O
system	I:C0282574
for	O
routine	O
diagnosis	O
of	O
bee	B:C1828283
venom	I:C1828283
(	I:C1828283
BV	I:C1828283
)	I:C1828283
allergy	I:C1828283
.	O

Now	O
,	O
there	O
are	O
five	O
components	O
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
rApi	B:C0002092
m	I:C0002092
1	I:C0002092
,	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
10	O
in	O
BV	O
-	I:C1828283
allergic	I:C1828283
patients	O
.	O

Now	O
,	O
there	O
are	O
five	O
components	O
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
,	O
2	B:C0002092
,	O
3	O
,	O
5	O
,	O
and	O
10	O
in	O
BV	O
-	I:C1828283
allergic	I:C1828283
patients	O
.	O

Now	O
,	O
there	O
are	O
five	O
components	O
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
,	O
2	O
,	O
3	B:C0002092
,	O
5	O
,	O
and	O
10	O
in	O
BV	O
-	I:C1828283
allergic	I:C1828283
patients	O
.	O

Now	O
,	O
there	O
are	O
five	O
components	O
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
,	O
2	O
,	O
3	O
,	O
5	B:C0002092
,	O
and	O
10	O
in	O
BV	O
-	I:C1828283
allergic	I:C1828283
patients	O
.	O

Now	O
,	O
there	O
are	O
five	O
components	O
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
,	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
10	B:C0002092
in	O
BV	O
-	I:C1828283
allergic	I:C1828283
patients	O
.	O

Now	O
,	O
there	O
are	O
five	O
components	O
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
,	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
10	O
in	O
BV	B:C1828283
-	I:C1828283
allergic	I:C1828283
patients	O
.	O

We	O
further	O
evaluated	O
the	O
sensitivity	O
of	O
rApi	B:C0002092
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
an	O
alternative	O
platform	O
and	O
investigated	O
possible	O
differences	O
in	O
the	O
sensitization	O
profile	O
between	O
monosensitization	O
and	O
clinically	O
relevant	O
double	O
sensitization	I:C1325847
.	O

We	O
further	O
evaluated	O
the	O
sensitivity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	B:C0002092
of	O
an	O
alternative	O
platform	O
and	O
investigated	O
possible	O
differences	O
in	O
the	O
sensitization	O
profile	O
between	O
monosensitization	O
and	O
clinically	O
relevant	O
double	O
sensitization	I:C1325847
.	O

We	O
further	O
evaluated	O
the	O
sensitivity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
an	O
alternative	O
platform	O
and	O
investigated	O
possible	O
differences	O
in	O
the	O
sensitization	B:C1325847
profile	O
between	O
monosensitization	O
and	O
clinically	O
relevant	O
double	O
sensitization	I:C1325847
.	O

We	O
further	O
evaluated	O
the	O
sensitivity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
an	O
alternative	O
platform	O
and	O
investigated	O
possible	O
differences	O
in	O
the	O
sensitization	O
profile	O
between	O
monosensitization	B:C1325847
and	O
clinically	O
relevant	O
double	O
sensitization	I:C1325847
.	O

We	O
further	O
evaluated	O
the	O
sensitivity	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
an	O
alternative	O
platform	O
and	O
investigated	O
possible	O
differences	O
in	O
the	O
sensitization	O
profile	O
between	O
monosensitization	O
and	O
clinically	O
relevant	O
double	B:C1325847
sensitization	I:C1325847
.	O

Analysis	B:C0936012
of	O
the	O
whole	O
panel	O
of	O
bee	O
venom	I:C0004920
allergens	O
of	O
the	O
CAP	O
system	I:C0282574
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	O
of	O
the	O
combination	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
the	O
Immulite	O
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O

Analysis	O
of	O
the	O
whole	O
panel	O
of	O
bee	B:C0004920
venom	I:C0004920
allergens	O
of	O
the	O
CAP	O
system	I:C0282574
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	O
of	O
the	O
combination	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
the	O
Immulite	O
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O

Analysis	O
of	O
the	O
whole	O
panel	O
of	O
bee	O
venom	I:C0004920
allergens	B:C0002092
of	O
the	O
CAP	O
system	I:C0282574
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	O
of	O
the	O
combination	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
the	O
Immulite	O
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O

Analysis	O
of	O
the	O
whole	O
panel	O
of	O
bee	O
venom	I:C0004920
allergens	O
of	O
the	O
CAP	B:C0282574
system	I:C0282574
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	O
of	O
the	O
combination	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
the	O
Immulite	O
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O

Analysis	O
of	O
the	O
whole	O
panel	O
of	O
bee	O
venom	I:C0004920
allergens	O
of	O
the	O
CAP	O
system	I:C0282574
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	B:C0936012
of	O
the	O
combination	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
the	O
Immulite	O
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O

Analysis	O
of	O
the	O
whole	O
panel	O
of	O
bee	O
venom	I:C0004920
allergens	O
of	O
the	O
CAP	O
system	I:C0282574
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	O
of	O
the	O
combination	O
of	O
rApi	B:C0002092
m	I:C0002092
1	I:C0002092
and	O
2	O
of	O
the	O
Immulite	O
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O

Analysis	O
of	O
the	O
whole	O
panel	O
of	O
bee	O
venom	I:C0004920
allergens	O
of	O
the	O
CAP	O
system	I:C0282574
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	O
of	O
the	O
combination	O
of	O
rApi	O
m	I:C0002092
1	I:C0002092
and	O
2	B:C0002092
of	O
the	O
Immulite	O
(	O
71.6	O
%	O
vs	O
85.8	O
%	O
)	O
.	O

Sensitization	B:C1325847
rate	O
of	O
rApi	O
m	I:C0002092
5	I:C0002092
was	O
more	O
than	O
doubled	O
in	O
double	O
-	I:C1325847
sensitized	I:C1325847
patients	O
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rApi	O
m	I:C0002092
2	I:C0002092
.	O

Sensitization	O
rate	O
of	O
rApi	B:C0002092
m	I:C0002092
5	I:C0002092
was	O
more	O
than	O
doubled	O
in	O
double	O
-	I:C1325847
sensitized	I:C1325847
patients	O
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rApi	O
m	I:C0002092
2	I:C0002092
.	O

Sensitization	O
rate	O
of	O
rApi	O
m	I:C0002092
5	I:C0002092
was	O
more	O
than	O
doubled	O
in	O
double	B:C1325847
-	I:C1325847
sensitized	I:C1325847
patients	O
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rApi	O
m	I:C0002092
2	I:C0002092
.	O

Sensitization	O
rate	O
of	O
rApi	O
m	I:C0002092
5	I:C0002092
was	O
more	O
than	O
doubled	O
in	O
double	O
-	I:C1325847
sensitized	I:C1325847
patients	O
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rApi	B:C0002092
m	I:C0002092
2	I:C0002092
.	O

The	O
benefit	O
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	B:C0004920
venom	I:C0004920
components	O
is	O
questionable	O
,	O
due	O
to	O
the	O
insufficient	O
sensitivity	O
and	O
still	O
unavailable	O
important	O
cross-reacting	O
allergens	O
.	O

The	O
benefit	O
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	O
venom	I:C0004920
components	O
is	O
questionable	O
,	O
due	O
to	O
the	O
insufficient	O
sensitivity	O
and	O
still	O
unavailable	O
important	O
cross-reacting	B:C0010357
allergens	O
.	O

The	O
benefit	O
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	O
venom	I:C0004920
components	O
is	O
questionable	O
,	O
due	O
to	O
the	O
insufficient	O
sensitivity	O
and	O
still	O
unavailable	O
important	O
cross-reacting	O
allergens	B:C0002092
.	O

